Product Description
Aurora B, also known as Aurora kinase B (ARKB), is a member of the serine/threonine kinase family and a core component of the chromosomal passenger complex (CPC) that plays a pivotal role in mitosis, including chromosome alignment, kinetochore-microtubule attachment, spindle assembly checkpoint control, and cytokinesis. Aurora B is activated through autophosphorylation and interaction with its regulatory subunits INCENP, survivin, and borealin. Beyond its essential physiological functions in accurate cell division, dysregulation of Aurora B—including overexpression, gene amplification, and aberrant activity—is frequently observed in a wide range of human cancers, such as breast, lung, colorectal, and hematologic malignancies, contributing to aneuploidy, tumor progression, and therapeutic resistance. These features have established Aurora B as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s Aurora B Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying Aurora B kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: Aurora B catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the Aurora B kinase.
Data